Last reviewed · How we verify
CM313 injection
At a glance
| Generic name | CM313 injection |
|---|---|
| Sponsor | Keymed Biosciences Co.Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of CM313 in Subject With IgA Nephropathy (PHASE2)
- Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness (PHASE1, PHASE2)
- Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) (PHASE2)
- A Single-center Study of CM313 in Patients With Pemphigus (NA)
- A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (PHASE2)
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia (PHASE1, PHASE2)
- Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) (PHASE2)
- A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM313 injection CI brief — competitive landscape report
- CM313 injection updates RSS · CI watch RSS
- Keymed Biosciences Co.Ltd portfolio CI